Montanova Capital LLC grew its holdings in shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report) by 16.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,300,000 shares of the company's stock after buying an additional 600,000 shares during the quarter. Montanova Capital LLC owned approximately 7.54% of Whitehawk Therapeutics worth $19,694,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Orbimed Advisors LLC bought a new position in shares of Whitehawk Therapeutics in the 3rd quarter valued at about $7,915,000. Acuta Capital Partners LLC bought a new stake in Whitehawk Therapeutics during the third quarter worth about $6,480,000. KVP Capital Advisors LP bought a new stake in Whitehawk Therapeutics during the fourth quarter worth about $5,242,000. Yu Fan acquired a new position in Whitehawk Therapeutics during the third quarter valued at approximately $3,933,000. Finally, BlackRock Inc. acquired a new position in Whitehawk Therapeutics during the second quarter valued at approximately $8,807,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
WHWK has been the topic of several recent analyst reports. Weiss Ratings lowered Whitehawk Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research report on Friday, June 5th. B. Riley Financial initiated coverage on Whitehawk Therapeutics in a report on Thursday, June 25th. They issued a "buy" rating and a $10.00 price objective for the company. Leerink Partners assumed coverage on shares of Whitehawk Therapeutics in a research note on Monday, July 13th. They issued an "outperform" rating and a $9.00 target price for the company. Wall Street Zen upgraded shares of Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $7.00 price target on shares of Whitehawk Therapeutics in a research report on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Whitehawk Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $8.20.
Check Out Our Latest Stock Report on Whitehawk Therapeutics
Whitehawk Therapeutics Stock Down 1.7%
Shares of NASDAQ WHWK opened at $4.54 on Tuesday. The business's 50 day moving average price is $4.27 and its two-hundred day moving average price is $4.01. The company has a market cap of $258.83 million, a PE ratio of -4.05 and a beta of 0.76. Whitehawk Therapeutics, Inc. has a twelve month low of $1.76 and a twelve month high of $5.49.
Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. As a group, research analysts anticipate that Whitehawk Therapeutics, Inc. will post -1.1 EPS for the current fiscal year.
Whitehawk Therapeutics Company Profile
(
Free Report)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Featured Articles
Want to see what other hedge funds are holding WHWK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Whitehawk Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Whitehawk Therapeutics wasn't on the list.
While Whitehawk Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
